White House withdraws FDA nomination for Dr. Heidi Overton
The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration in the face of Senate opposition to her candidacy, according to a White House official and two sources familiar with the matter, reports BritPanorama.
This decision comes as Overton faces skepticism from multiple senators ahead of a committee vote scheduled for Wednesday, which would have determined the fate of her nomination.
Recent efforts by Trump officials aimed to secure support from key senators, including abortion rights proponents such as Sen. Susan Collins and Sen. Lisa Murkowski, alongside abortion rights opponent Sen. Josh Hawley, two individuals with knowledge of the discussions indicated.
Overton’s nomination has also highlighted divisions within the “Make America Healthy Again” (MAHA) movement, led by Health and Human Services Secretary Robert F. Kennedy Jr., and more traditional conservative factions.
As a senior White House domestic policy adviser, Overton had served as the primary link between HHS officials pursuing key MAHA policies and top Trump White House figures, who have recently stalled those efforts, contributing to frustration and distrust within the broader movement.
Although Kennedy endorsed her nomination in August, sources familiar with their interactions have described their relationship as strained.
When asked about Overton’s rapport with Kennedy shortly after her FDA selection, one source characterized it as “not good.” Another person described their interactions as “icy.” “She’s not MAHA,” noted another individual familiar with the dynamic.
The Health, Education, Labor and Pensions Committee was also set to vote Wednesday morning on advancing Jim O’Neill’s nomination to helm the National Science Foundation, as well as candidates for senior labor and education positions. A spokesperson for the HELP Committee did not immediately respond to queries about the other votes.
Axios was first to report the Trump administration’s decision to withdraw Overton’s nomination.
Developments surrounding the FDA nomination reflect ongoing tensions within the Trump administration and its relationship with various factions within the party.